MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
$17,466,285
EPS
-$0.14
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
7,187,235
5,254,966
2,424,346*
925,377
General and administrative
3,454,924
11,416,586
3,350,878.5*
1,918,971
Total expenses
10,642,159
16,671,552
5,775,224.5
2,844,348
Loss from operations
-10,642,159
-16,671,552
-5,775,224.5*
-2,844,348
Foreign exchange losses
-14,351
-1,804
-15,521*
-6,246
Investment income
569,591
629,602
583,155.5*
106,640
Loss on issuance of convertible preferred stock and warrants
-
-
289,783,590.75*
-
Warrant issuance cost
-
-
775,662.25*
-
Changes in fair value of the warrant liability
-27,553,204
109,360,630
-11,347,479*
-
Net income (loss)
17,466,285
-125,404,384
-284,419,364
-2,743,954
Basic EPS
0.36
-2.86
-27.741
-0.36
Diluted EPS
-0.14
-2.86
-27.741
-0.36
Basic Average Shares
46,599,044
43,900,426
10,252,781
7,568,981
Diluted Average Shares
79,104,585
43,900,426
10,252,781
7,568,981
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Changes in fair value of
the warrant...
-$27,553,204
Investment income
$569,591
(316.76%↑ Y/Y)
Net income (loss)
$17,466,285
(636.01%↑ Y/Y)
Loss from operations
-$10,642,159
(-215.40%↓ Y/Y)
Foreign exchange losses
-$14,351
(32.02%↑ Y/Y)
Total expenses
$10,642,159
(215.40%↑ Y/Y)
Research and development
$7,187,235
(453.70%↑ Y/Y)
General and
administrative
$3,454,924
(66.41%↑ Y/Y)
Buy us a coffee
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)